公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2023 | Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301 | Cho, Byoung Chul; Ahn, Myung-Ju; Kang, Jin Hyoung; Soo, Ross A; Reungwetwattana, Thanyanan; CHIH-HSIN YANG ; Cicin, Irfan; Kim, Dong-Wan; Wu, Yi-Long; Lu, Shun; Lee, Ki Hyeong; Pang, Yong-Kek; Zimina, Anastasia; Fong, Chin Heng; Poddubskaya, Elena; Sezer, Ahmet; How, Soon Hin; Danchaivijitr, Pongwut; Kim, YuKyung; Lim, Yeji; An, Taewon; Lee, Hana; Byun, Hae Mi; Zaric, Bojan | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 11 | 1 | |
2016 | LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts | Ramalingam S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Jänne P.A. | Journal of Thoracic Oncology | 66 | 57 | |
2016 | LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results | CHIH-HSIN YANG ; Ramalingam S.S; Jänne P.A; Cantarini M; Mitsudomi T. | Journal of Thoracic Oncology | 89 | 82 | |
2022 | LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer | Tsuboi, Masahiro; Goldman, Jonathan W; Wu, Yi-Long; Johnson, Melissa L; Paz-Ares, Luis; CHIH-HSIN YANG ; Besse, Benjamin; Su, Weiji; Chao, Bo H; Drilon, Alexander | Future oncology (London, England) | 9 | 7 | |
1995 | Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes | KUN-HUEI YEH ; Lin M. T.; JIH-LUH TANG ; CHIH-HSIN YANG ; WOEI TSAY ; YAO-CHANG CHEN | British Journal of Haematology | 19 | 14 | |
2021 | Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC | Awad M.M.; Gadgeel S.M.; Borghaei H.; Patnaik A.; CHIH-HSIN YANG ; Powell S.F.; Gentzler R.D.; Martins R.G.; Stevenson J.P.; Altan M.; Jalal S.I.; Panwalkar A.; Gubens M.; Sequist L.V.; Saraf S.; Zhao B.; Piperdi B.; Langer C.J. | Journal of Thoracic Oncology | 94 | 77 | |
2021 | Lung Cancer in Republic of China | Luo Y.-H.; Chiu C.-H.; Scott Kuo C.-H.; Chou T.-Y.; Yeh Y.-C.; Hsu H.-S.; Yen S.-H.; Wu Y.-H.; CHIH-HSIN YANG ; BIN-CHI LIAO ; Hsia T.-C.; Chen Y.-M. | Journal of Thoracic Oncology | 33 | 26 | |
2008 | Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response | Wu J.-Y.; SHANG-GIN WU ; CHIH-HSIN YANG ; Gow C.-H.; YIH-LEONG CHANG ; CHONG-JEN YU ; Shin J.-Y.; PAN-CHYR YANG | Clinical Cancer Research | 278 | 250 | |
2012 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 | Ohashi K; Sequist L.V; Arcila M.E; Moran T; Chmielecki J; Lin Y.-L; Pan Y; Wang L; De Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; CHIH-HSIN YANG ; Miller V.A; Riely G.J; Kris M.G; Engelman J.A; Vnencak-Jones C.L; Dias-Santagata D; Ladanyi M; Pao W. | Proceedings of the National Academy of Sciences of the United States of America | 386 | 366 | |
1993 | Lymphoblast colony-culture assay in acute lymphoblastic leukemia: A quantitative approach | RUEY-LONG HONG ; Shen S.-W.; Lin M.-T.; HWEI-FANG TIEN ; CHIH-HSIN YANG ; YAO-CHANG CHEN | Leukemia Research | 3 | 1 | |
2021 | Lysine deprivation induces AKT-AADAT signaling and overcomes EGFR-TKIs resistance in EGFR-mutant non-small cell lung cancer cells | Hsu C.-C.; Yang A.Y.-P.; Chen J.-Y.; Tsai H.-H.; Lin S.-H.; Tai P.-C.; Huang M.-H.; Hsu W.-H.; Lin A.M.-Y.; CHIH-HSIN YANG | Cancers | 5 | 5 | |
2018 | Management of Toxicities of Targeted Therapies | CHIH-HSIN YANG ; CHIA-CHI LIN ; CHIA-YU CHU | IASLC Thoracic Oncology | 4 | 0 | |
2016 | Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer | SHAO-LUN LU ; Feng-Ming Hsu ; KUAN-YU CHEN ; CHAO-CHI HO ; CHIH-HSIN YANG ; CHIA-HSIEN CHENG | Case Reports in Oncology | 2 | 0 | |
2016 | The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients | SHANG-GIN WU ; Liu Y.-N.; Tsai M.-F.; YIH-LEONG CHANG ; CHONG-JEN YU ; PAN-CHYR YANG ; CHIH-HSIN YANG ; Wen Y.-F.; JIN-YUAN SHIH | Oncotarget | 204 | 191 | |
2013 | MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib | Huang M.-H.; JIH-HSIANG LEE ; Chang Y.-J.; Tsai H.-H.; Lin Y.-L.; Lin A.M.Y.; CHIH-HSIN YANG | Molecular Oncology | 71 | 63 | |
2007 | Melatonin attenuates arsenite-induced apoptosis in rat brain: Involvement of mitochondrial and endoplasmic reticulum pathways and aggregation of α-synuclein | Lin A.M.Y; Fang S.F; Chao P.L; CHIH-HSIN YANG | Journal of Pineal Research | 76 | 70 | |
2009 | Melatonin inhibits arsenite-induced peripheral neurotoxicity | Lin A.M.Y; Feng S.F; Chao P.L; CHIH-HSIN YANG | Journal of Pineal Research | 24 | 24 | |
2007 | MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Bean J.; Brennan C.; JIN-YUAN SHIH ; Riely G.; Viale A.; Wang L.; Chitale D.; Motoi N.; Szoke J.; Broderick S.; Balak M.; Chang W.-C.; CHONG-JEN YU ; Gazdar A.; Pass H.; Rusch V.; Gerald W.; Huang S.-F.; PAN-CHYR YANG ; Miller V.; Ladanyi M.; CHIH-HSIN YANG ; Pao W. | Proceedings of the National Academy of Sciences of the United States of America | 1511 | 1379 | |
2016 | Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer | Lu S; Cheng Y; Zhou C.-C; Wang J; Chih-Hsin CHIH-HSIN YANG ; Zhang P.-H; Zhang X.-Q; Wang X; Orlando M; Wu Y.-L. | Clinical Lung Cancer | 10 | | |
2017 | Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial | Thress K.S; Jacobs V; Angell H.K; CHIH-HSIN YANG ; Sequist L.V; Blackhall F; Su W.-C; Schuler M; Wolf J; Gold K.A; Cantarini M; Barrett J.C; Jänne P.A. | Journal of Thoracic Oncology | 19 | 19 | |